RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Shanghai Fosun Pharmaceutical Group Co Stock

Shanghai Fosun Pharmaceutical Group Co EBIT 2024

Shanghai Fosun Pharmaceutical Group Co EBIT

2.26 B CNY

Ticker

600196.SS

ISIN

CNE000000X38

In 2024, Shanghai Fosun Pharmaceutical Group Co's EBIT was 2.26 B CNY, a 76.08% increase from the 1.29 B CNY EBIT recorded in the previous year.

The Shanghai Fosun Pharmaceutical Group Co EBIT history

YEAREBIT (undefined CNY)
2026e2.79
2025e2.63
2024e2.26
20231.29
20223.5
20212.55
20202.64
20192.49
20182.29
20172.24
20161.64
20151.36
20141.11
20131.03
20120.55
20110.32
20100.16
20090.16
20080.12
20070.16
20060.09
20050.14
20040.15

Shanghai Fosun Pharmaceutical Group Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Shanghai Fosun Pharmaceutical Group Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Shanghai Fosun Pharmaceutical Group Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Shanghai Fosun Pharmaceutical Group Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Shanghai Fosun Pharmaceutical Group Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Shanghai Fosun Pharmaceutical Group Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Shanghai Fosun Pharmaceutical Group Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Shanghai Fosun Pharmaceutical Group Co’s growth potential.

Shanghai Fosun Pharmaceutical Group Co Revenue, EBIT and net profit per share

DateShanghai Fosun Pharmaceutical Group Co RevenueShanghai Fosun Pharmaceutical Group Co EBITShanghai Fosun Pharmaceutical Group Co Net Income
2026e51.85 B undefined2.79 B undefined3.78 B undefined
2025e48.53 B undefined2.63 B undefined3.32 B undefined
2024e44.88 B undefined2.26 B undefined2.82 B undefined
202341.4 B undefined1.29 B undefined2.39 B undefined
202243.95 B undefined3.5 B undefined3.73 B undefined
202139.01 B undefined2.55 B undefined4.74 B undefined
202030.31 B undefined2.64 B undefined3.66 B undefined
201928.59 B undefined2.49 B undefined3.32 B undefined
201824.92 B undefined2.29 B undefined2.71 B undefined
201718.53 B undefined2.24 B undefined3.12 B undefined
201614.63 B undefined1.64 B undefined2.81 B undefined
201512.61 B undefined1.36 B undefined2.46 B undefined
201412.03 B undefined1.11 B undefined2.11 B undefined
201310 B undefined1.03 B undefined1.58 B undefined
20127.34 B undefined553 M undefined1.56 B undefined
20116.49 B undefined324 M undefined1.17 B undefined
20104.56 B undefined163 M undefined864 M undefined
20093.87 B undefined157 M undefined2.5 B undefined
20083.77 B undefined118 M undefined691 M undefined
20073.69 B undefined164 M undefined626 M undefined
20064.08 B undefined92 M undefined258 M undefined
20052.99 B undefined143 M undefined159 M undefined
20042.43 B undefined153 M undefined215 M undefined

Shanghai Fosun Pharmaceutical Group Co stock margins

The Shanghai Fosun Pharmaceutical Group Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Shanghai Fosun Pharmaceutical Group Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Shanghai Fosun Pharmaceutical Group Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Shanghai Fosun Pharmaceutical Group Co's sales revenue. A higher gross margin percentage indicates that the Shanghai Fosun Pharmaceutical Group Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Shanghai Fosun Pharmaceutical Group Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Shanghai Fosun Pharmaceutical Group Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Shanghai Fosun Pharmaceutical Group Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Shanghai Fosun Pharmaceutical Group Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Shanghai Fosun Pharmaceutical Group Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Shanghai Fosun Pharmaceutical Group Co Margin History

Shanghai Fosun Pharmaceutical Group Co Gross marginShanghai Fosun Pharmaceutical Group Co Profit marginShanghai Fosun Pharmaceutical Group Co EBIT marginShanghai Fosun Pharmaceutical Group Co Profit margin
2026e47.54 %5.37 %7.3 %
2025e47.54 %5.42 %6.84 %
2024e47.54 %5.04 %6.29 %
202347.54 %3.11 %5.76 %
202247.09 %7.97 %8.49 %
202147.97 %6.54 %12.14 %
202055.47 %8.72 %12.09 %
201959.57 %8.71 %11.62 %
201858.34 %9.17 %10.87 %
201758.84 %12.06 %16.86 %
201653.81 %11.23 %19.18 %
201549.78 %10.81 %19.51 %
201443.87 %9.19 %17.57 %
201344.22 %10.3 %15.84 %
201243.62 %7.53 %21.31 %
201137.63 %5 %17.98 %
201033.9 %3.58 %18.97 %
200932.02 %4.05 %64.51 %
200827.67 %3.13 %18.31 %
200726.59 %4.44 %16.95 %
200621.34 %2.25 %6.32 %
200529.98 %4.78 %5.32 %
200431.22 %6.31 %8.87 %

Shanghai Fosun Pharmaceutical Group Co Aktienanalyse

What does Shanghai Fosun Pharmaceutical Group Co do?

Shanghai Fosun Pharmaceutical Group Co Ltd is a Chinese company specializing in the healthcare industry. It was founded in 1994 and is headquartered in Shanghai. The company has grown to become one of the largest pharmaceutical conglomerates in China and operates internationally. The company's history began in the 1990s with the establishment of Shanghai Fosun High-Tech (Group) Co. Ltd. Through the acquisition of local pharmaceutical companies, Fosun quickly secured a place among the major players in the Chinese pharmaceutical market. From the beginning, the development, production, and marketing of pharmaceutical products and medical devices were the main focus. Today, Shanghai Fosun Pharmaceutical is a holding company with various subsidiaries operating in different areas of medicine. These include the development of innovative drugs, the production of generic drugs, and the business-to-consumer sector. The company generates an annual revenue of over six billion US dollars. One of Shanghai Fosun Pharmaceutical's most well-known products is the drug Alunbrig for the treatment of lung cancer. It is a tyrosine kinase inhibitor that inhibits the growth of cancer cells. Alunbrig has shown good results in clinical studies and is now approved for the treatment of lung cancer in many countries. Another important business area for Shanghai Fosun Pharmaceutical is the production of generic drugs. These are imitations of already approved, often expensive, original drugs. Fosun manufactures such medications at a significantly lower cost than the original manufacturer, making them more accessible to a broader population. In addition to drug development and generic production, Shanghai Fosun Pharmaceutical is also active in other areas of the healthcare industry. In recent years, the company has acquired several private hospitals in China and operates them under the name Fosun International Hospitals. Special emphasis is placed on state-of-the-art medical technology and patient-oriented care. Another important area is the manufacturing of medical devices. Shanghai Fosun Pharmaceutical works closely with partners from both domestic and foreign markets to develop innovative products. An example is the artificial hip joint, which was developed in collaboration with an American partner company. Fosun produces and distributes over 70 different types of medical devices. In summary, Shanghai Fosun Pharmaceutical Group is an innovative company specializing in various areas of the healthcare industry. Through its consistent focus on growth and innovation, Fosun has steadily expanded in recent years and has become one of the key players in the Chinese pharmaceutical market. However, the global expansion and ambitious goals also leave room for risks and mistakes. Shanghai Fosun Pharmaceutical Group Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Shanghai Fosun Pharmaceutical Group Co's EBIT

Shanghai Fosun Pharmaceutical Group Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Shanghai Fosun Pharmaceutical Group Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Shanghai Fosun Pharmaceutical Group Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Shanghai Fosun Pharmaceutical Group Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Shanghai Fosun Pharmaceutical Group Co stock

How much did Shanghai Fosun Pharmaceutical Group Co achieve in EBIT for the current year?

In the current year, Shanghai Fosun Pharmaceutical Group Co has achieved an EBIT of 2.26 B CNY.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Shanghai Fosun Pharmaceutical Group Co.

How has the EBIT of Shanghai Fosun Pharmaceutical Group Co developed in recent years?

The EBIT of Shanghai Fosun Pharmaceutical Group Co has increased by 76.08% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Shanghai Fosun Pharmaceutical Group Co?

The EBIT of Shanghai Fosun Pharmaceutical Group Co is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Shanghai Fosun Pharmaceutical Group Co pay?

Over the past 12 months, Shanghai Fosun Pharmaceutical Group Co paid a dividend of 0.42 CNY . This corresponds to a dividend yield of about 1.89 %. For the coming 12 months, Shanghai Fosun Pharmaceutical Group Co is expected to pay a dividend of 0.44 CNY.

What is the dividend yield of Shanghai Fosun Pharmaceutical Group Co?

The current dividend yield of Shanghai Fosun Pharmaceutical Group Co is 1.89 %.

When does Shanghai Fosun Pharmaceutical Group Co pay dividends?

Shanghai Fosun Pharmaceutical Group Co pays a quarterly dividend. This is distributed in the months of August, July, September, September.

How secure is the dividend of Shanghai Fosun Pharmaceutical Group Co?

Shanghai Fosun Pharmaceutical Group Co paid dividends every year for the past 23 years.

What is the dividend of Shanghai Fosun Pharmaceutical Group Co?

For the upcoming 12 months, dividends amounting to 0.44 CNY are expected. This corresponds to a dividend yield of 2 %.

In which sector is Shanghai Fosun Pharmaceutical Group Co located?

Shanghai Fosun Pharmaceutical Group Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shanghai Fosun Pharmaceutical Group Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shanghai Fosun Pharmaceutical Group Co from 8/6/2024 amounting to 0.27 CNY, you needed to have the stock in your portfolio before the ex-date on 8/6/2024.

When did Shanghai Fosun Pharmaceutical Group Co pay the last dividend?

The last dividend was paid out on 8/6/2024.

What was the dividend of Shanghai Fosun Pharmaceutical Group Co in the year 2023?

In the year 2023, Shanghai Fosun Pharmaceutical Group Co distributed 0.56 CNY as dividends.

In which currency does Shanghai Fosun Pharmaceutical Group Co pay out the dividend?

The dividends of Shanghai Fosun Pharmaceutical Group Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Shanghai Fosun Pharmaceutical Group Co

Our stock analysis for Shanghai Fosun Pharmaceutical Group Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shanghai Fosun Pharmaceutical Group Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.